Navigation Links
BioMarin Announces Third Quarter 2009 Financial Results
Date:10/28/2009

------- ------- Total liabilities and stockholders' equity $906,695 $869,357 ======== ======== (1) December 31, 2008 balances were derived from the audited consolidated financial statements.
                  BIOMARIN PHARMACEUTICAL INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF OPERATIONS
         For the Three and Nine Months Ended September 30, 2008 and 2009
               (In thousands, except for per share data, unaudited)

                                        Three Months          Nine Months
                                           Ended                 Ended
                                        September 30,        September 30,
                                        -------------        -------------
                                        2008     2009        2008     2009
                                        ----     ----        ----     ----
     Revenues:
        Net product revenues         $67,812   $78,383   $185,895   $231,769
        Collaborative agreement
         revenues                      2,414       648      7,389      2,025
        Royalty and license
         revenues                      2,420     1,776      3,933      3,780
                                       -----     -----      -----      -----

            Total revenues            72,646    80,807    197,217    237,574
                                      ------    ------    -------    -------

     Operating expenses:
        Cost of sales                 14,063    14,970     40,844     49,180
        Research and development      26,175    26,991     67,559     87,673
        Selling, general and
         administrative               28,964    28,667     77,836     87,762
        Amortization of acquired
         intangible assets             1,093        46      3,278      2,914
                    
'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. BioMarin to Present at the Oppenheimer Healthcare Conference
2. BioMarin Acquires Huxley Pharmaceuticals, Inc.
3. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
4. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
5. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
6. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
7. BioMarin Announces FDA Approval for Kuvan
8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
9. Rigel Announces Presentations at Two Investor Conferences
10. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
11. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 1, 2015 Eli Lilly and Company (NYSE: ... quarter of 2015 on Thursday, April 23, 2015.  Lilly will ... investment community and media to further detail the company,s financial ... a.m. EDT. Investors, media, and the general public can access ... that will be posted on Lilly,s website at www.lilly.com ...
(Date:4/1/2015)... DALLAS , April 1, 2015 /PRNewswire/ ... Research Report on Global Azithromycin Industry and ... Drug Industry reports added to Pharmaceutical category ... analysis, the report introduces Azithromycin basic information, ... industry overview, policy analysis, and news analysis, ...
(Date:4/1/2015)... April 1, 2015  Egalet Corporation (Nasdaq: ... company focused on developing, manufacturing and marketing innovative ... offering of $60.0 million aggregate principal amount of ... in a private placement to qualified institutional buyers ... of 1933, as amended (the "Act"). Egalet also ...
Breaking Medicine Technology:Lilly Confirms Date and Conference Call for First-Quarter 2015 Financial Results Announcement 2Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 2Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 3Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 4Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 5Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 2Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 3Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 4Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 5Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 6Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 7
... Stereotaxis, Inc. (NASDAQ:   STXS) today announced that ... Epoch platform, its comprehensive solution for the electrophysiology ... in procedures with a fully-remote, networked robotic and ... to the new generation Epoch platform from the ...
... -- Breadth of Pharmacokinetic Data Points to Tunable ... novel preclinical in vitro and in ... in an oral presentation at the American Society of ... presentation entitled "Discovery and Preclinical Characterization of a Novel ...
Cached Medicine Technology:Stereotaxis Announces Initial Shipments of the Epoch™ Platform to Customers 2Stereotaxis Announces Initial Shipments of the Epoch™ Platform to Customers 3Stereotaxis Announces Initial Shipments of the Epoch™ Platform to Customers 4Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin(R) Program at ASH Annual Meeting 2Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin(R) Program at ASH Annual Meeting 3
(Date:4/1/2015)... 01, 2015 Taking an important step ... League for Nursing Commission for Nursing Education Accreditation (NLN ... the first NLN CNEA Board of Commissioners. Working with ... the 15-member board will provide leadership and direction to ... accreditation decisions for nursing programs that seek accreditation from ...
(Date:4/1/2015)... Minn. (PRWEB) April 01, 2015 EAGAN, ... of Minnesota and its family of companies (Blue Cross) ... closed out the year with net income of $61.5 ... operational losses. The organization reported a net operating loss ... for a negative operating margin of one-tenth of one ...
(Date:4/1/2015)... San Diego, CA (PRWEB) April 01, 2015 ... promotion organization, is announcing two continuing medical education ... goal is to help practitioners become more confident ... to prevent disease. After completion of these CME ... , The CME courses available are ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Aging2.0 ... care, today announces the launch of the Aging2.0 ... senior care stakeholders and technology companies. The announcement was ... (NIC) Capital and Business Strategies Forum in San ... the new Alliance program is now open for additional ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 When annoying ... occur, waiting days or weeks for an appointment with ... same and next day appointments haven’t been possible within ... Forefront Dermatology’s offices have noticed demand for this level ... “We realize how important relief or answers to dermatological ...
Breaking Medicine News(10 mins):Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 2Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 3Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 2Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 3Health News:GrassrootsHealth Launches CME Courses about Vitamin D 2Health News:GrassrootsHealth Launches CME Courses about Vitamin D 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 2Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 4Health News:Dermatology Associates of Wisconsin and Forefront Dermatology Answers Patients' Needs With Unmatched Availability In Sheboygan and Sheboygan Falls 2
... new study shows that a large majority of patients who present ... IV) don,t require immediate surgery to remove the primary tumor in ... data today at the American Society of Clinical Oncology Annual Meeting. ... "For this population with metastatic ...
... May 30 Wyeth Pharmaceuticals, a division of Wyeth ... The American Society of Clinical Oncology (ASCO) Cancer Foundation ... provide patients with important health information and conduct physician ... the 45th Annual Meeting of the American Society of ...
... contradicted in research paper , , FRIDAY, May 29 (HealthDay ... follow a social order do not necessarily develop bigger ... Social Brain Hypothesis followed by many evolutionists. , ... Proceedings of the National Academy of Sciences ...
... the most common reason for hospitalisation in the over-65 ... 24 hours after admission in around 50% of these ... a more than 50% mortality and rehospitalisation rate at ... Cardiology Department of the University of Brescia, Italy, "it ...
... biomarkers have been recently described in Heart Failure (HF) ... settings of acute decompensation. Biomarkers are used to diagnose ... to individuals. , Speaking at a press conference at ... spokesperson for the European Society of Cardiology, presented these ...
... the symptoms of heart failure can be remotely assessed, ... of patients, according to Professor John Cleland from the ... 2009 that the management of heart failure is complex ... needs and condition.2 "Unfortunately," he added, "the resources required ...
Cached Medicine News:Health News:Surgery not necessary for most late-stage colorectal cancers 2Health News:Wyeth Donates $100,000 to ASCO Cancer Foundation(R) to Support Cancer Prevention and Care 2Health News:Wyeth Donates $100,000 to ASCO Cancer Foundation(R) to Support Cancer Prevention and Care 3Health News:Biologists Question Animal Brain Size Theory 2Health News:Better treatment selection and improved therapies -- key to improving prognosis in acute HF 2Health News:Novel biomarkers in heart failure 2Health News:Individualized treatment for heart failure is rarely available outside hospital 2
The VersaFluor cuvette fluorometer is a fast and simple way to quantitate DNA, RNA, and proteins, to detect apoptosis, and to perform reporter enzyme assays with the high level of sensitivity and sel...
... DyNA Quant™ 200 is a ... excitation and 460 nm emission. The ... the detection of double-stranded DNA using ... assay, which minimizes interference from the ...
... fluorometer from Berthold Technologies, has been ... of measurement modes to support academic ... dual ratio measurements plus top and ... instrument for any researcher using fluorescence ...
The TBS-380 Fluorometer is an economical, sensitive fluorometer designed for quick, easy, and accurate fluorescent measurements....
Medicine Products: